secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041312
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics Q2 net loss $7.1M; cash $94.2M; three chronic cough trials on track for H2 2023
--------------------------------------------------------------------------------

- Net loss of $7.1M in Q2 2023 vs. $8.1M in Q2 2022; R&D expenses rose to $5.8M.
- Cash, cash equivalents and marketable securities $94.2M at June 30, 2023.
- Plans to initiate three chronic cough trials (Phase 2b IPF, Phase 1b IPF, Phase 2a RCC) in H2 2023 remain on track.
- Human Abuse Potential study delayed due to IV butorphanol shortage from supplier tornado damage.
- Phase 2 CANAL trial data published in NEJM Evidence; term loan of $6.5M repaid in May 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017023041312/0000950170-23-041312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017023041312/trvi-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer